Rapport Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.36B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $20.00M | $-0.42 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | Before market open | – | $-0.72 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-0.75 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | $-0.68 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | Before market open | – | $-0.57 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-1.70 | – |
Press releases
Announcements Rapport Therapeutics filed with the SEC
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
RAP-219 dose-exposure-RO relationship Preclinical models demonstrated maximal seizure protection at 50-70% RO (green band) All Phase 3 FOS trial doses achieve target RO RO: Receptor occupancy.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
January 2026 Corporate Presentation Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Seizures Topline Results Conference Call Presentation September 8, 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
RAP-219 Phase 2a trial in patients with focal onset seizures Goal: Generate data from ≥20 participants showing convincing reductions in long episodes and clinical seizures to support advancement to registrational studies
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Investor & Analyst Day June 2, 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Disclaimer This presentation contains “forward-looking
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
Results of operations · EX-99.1 to Form 8-K